Journals / Genel Tıp Dergisi / 2023 / Cilt: 33 Sayı: 3

COVID-19 Ricochets on Kidney Transplant and Hemodialysis Patients

Böbrek Nakli ve Hemodiyaliz Hastalarında COVID-19 Rikoşeleri

Pages
309–315
Publication Date
2023-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Early hospitalization and treatment implementations will be associated with a good prognosis in HD and KTx patients since CT and laboratory results are not predictive in these groups of patients during the COVID-19 pandemic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: An impaired immune response affects Coronavirus 2019 (COVID-19) disease progression.
📊
Key Findings & Data:This study evaluated the prognostic laboratory results in HD and KTx patients with COVID-19.
💡
Conclusion & Impact:Conclusions: Early hospitalization and treatment implementations will be associated with a good prognosis in HD and KTx patients since CT and laboratory results are not predictive in these groups of patients during the COVID-19 pandemic.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:COVID-19 · Böbrek nakli · Hemodiyaliz

Abstract

Background/Aims: An impaired immune response affects Coronavirus 2019 (COVID-19) disease progression. Immunities of both hemodialysis (HD) and Kidney Transplant (KTx) patients have already been suppressed. This study evaluated the prognostic laboratory results in HD and KTx patients with COVID-19. Methods: This retrospective, case-control study was conducted with PCR (+) COVID-19 HD and KTx patients and a control group. All patients were divided into two subgroups according to disease severity. Patients' demographic records and laboratory results were obtained from the follow-up files. Results: A total of 30 HD, 20 KTx patients, and 40 control groups were involved in the study. Gender and hospitalization duration did not differ between the groups. There was a 10% mortality rate in the KTx group and 27% in the HD group. Lung involvement in Computed Tomography (CT) was higher in HD patients (47%) than in KTx (25%). In subgroup evaluations, the most prominent laboratory values were fibrinogen in HD patients and LDH and Ferritin in KTx patients in determining disease severity. Conclusions: Early hospitalization and treatment implementations will be associated with a good prognosis in HD and KTx patients since CT and laboratory results are not predictive in these groups of patients during the COVID-19 pandemic.

Özet

Arka Plan/Amaçlar: Bozulmuş bir bağışıklık cevabı, Coronavirüs 2019 (COVID-19) hastalığının prognozunu etkiler. Hem hemodiyaliz (HD) hem de Böbrek Nakli (BN) hastalarının bağışıklıkları zaten baskılıdır. Bu çalışma COVID-19'lu HD ve BN hastalarında prognostik laboratuvar sonuçlarını değerlendirmiştir. Yöntemler: Bu retrospektif, vaka kontrol çalışması, PCR (+) COVID-19 HD ve BN hastaları ve kontrol grubu ile gerçekleştirildi. Tüm hastalar hastalık şiddetine göre iki alt gruba ayrıldı. Hastaların demografik kayıtları ve laboratuvar sonuçları takip dosyalarından elde edildi. Bulgular: Çalışmaya toplam 30 HD, 20 BN hastası ve 40 kontrol grubu dahil edildi. Cinsiyet ve hastanede yatış süresi gruplar arasında farklılık göstermedi. BN grubunda %10, HD grubunda %27 ölüm oranı vardı. Bilgisayarlı Tomografide (BT) akciğer tutulumu HD hastalarında (%47) BN'ye (%25) göre daha yüksekti. Alt grup değerlendirmelerinde hastalık şiddetinin belirlenmesinde HD hastalarında fibrinojen, BN hastalarında ise LDH ve Ferritin öne çıkan laboratuvar değerleriydi. Sonuç: BT ve laboratuvar sonuçları COVID-19 pandemisinde bu tarz hasta gruplarında prediktif olmadığı için erken yatış ve tedavi uygulamaları HD ve BN hastalarında iyi bir prognoz ile ilişkili olacaktır.

🔖

Cite This Article

GÖKTEPE, M. H., ÇİZMECİOGLU, H. A., TUNA, A. K., CİZMECİOGLU, A. (2023). COVID-19 Ricochets on Kidney Transplant and Hemodialysis Patients. Genel Tıp Dergisi, Cilt: 33 Sayı: 3, 309–315. https://ajindex.com/articles/951538

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. BMJ 2020;368:m1036 WHO (2022) Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/. Accessed 19 April 2022
  2. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020;395(10229):1014-1015
  3. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288(2):192-206
  4. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int 2020;97(6):1083-1088
  5. W. Guan, Z. Ni, Yu Hu, W. Liang, C. Ou, J. He, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382(18):1708-1720
  6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323(11):1061-1069
  7. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med 2020;35(5):1545-1549
  8. Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and Solid Organ Transplantation: A Review Article. Transplantation 2021;105(1):37-55
  9. Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr 2012;22(1):149-56
  10. Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020;83(6):521-523
  11. Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5(7):667-678
  12. Dashti-Khavidaki S, Khalili H, Nourian A. Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review. Iran J Kidney Dis 2020;14(4):247-255. Coulter CV. The role of the suspicious renal pharmacist in identifying unusual adverse drug reactions-why this is not a small problem. Int J Clin Pharm 2018;40(4):775-777 https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
  13. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a d